Use of the prevented fraction for the population to determine deaths averted by existing prevalence of physical activity

Citation for published version:
Strain, T, Brage, S, Sharp, SJ, Richards, J, Tainio, M, Ding, D, Benichou, J & Kelly, P 2020, 'Use of the prevented fraction for the population to determine deaths averted by existing prevalence of physical activity: A descriptive study', The Lancet Global Health, vol. 8, no. 7, pp. e920-e930. https://doi.org/10.1016/S2214-109X(20)30211-4

Digital Object Identifier (DOI):
10.1016/S2214-109X(20)30211-4

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
The Lancet Global Health

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Use of the prevented fraction for the population to determine deaths averted by existing prevalence of physical activity: a descriptive study

Tessa Strain, Søren Brage, Stephen J Sharp, Justin Richards, Marko Tainio, Ding Ding, Jacques Benichou, Paul Kelly

Summary
Background Disease and mortality burdens of unhealthy lifestyle behaviours are often reported. In contrast, the positive narrative around the burdens that an existing behaviour have averted is rarely acknowledged. We aimed to estimate the prevented fraction for the population (PFP) for premature mortality averted by physical activity on a global scale.

Methods In this descriptive study, we obtained previously published data on physical activity prevalence (2001–16) and relative risks of all-cause mortality for 168 countries. We combined the data in Monte-Carlo simulations to estimate country-specific, mean PFP values, corresponding to percentage of mortality averted, and their 95% CIs. High prevented fractions indicated an increased proportion of deaths averted due to physical activity. Using mortality data for all people in a country aged 40–74 years, we estimated the number of premature deaths averted for all adults and by gender. We present the median and range of the prevented fractions globally, by WHO region, and by World Bank income classification.

Findings The global median PFP was 15·0% (range 6·6–20·5), conservatively equating to 3·9 million (95% CI 2·5–5·6) premature deaths averted annually. The African region had the highest median prevented fraction (16·6% [range 12·1–20·5]) and the Americas had the lowest (13·1% [10·8–16·6]). Low-income countries tended to have higher prevented fractions (group median 17·9% [12·3–20·5]) than high-income countries (14·1% [6·6–17·8]). Globally, the median prevented fraction was higher for men (16·0% [7·8–20·7]) than women (14·1% [5·0–20·4]).

Interpretation Existing physical activity prevalence has contributed to averting premature mortality across all countries. PFP has utility as an advocacy tool to promote healthy lifestyle behaviours. By making the case of what has been achieved, the prevented fraction can show the value of current investment and services, which might be conducive to political support.

Funding UK Medical Research Council, British Heart Foundation, Cancer Research UK, Economic and Social Research Council, National Institute for Health Research, Wellcome Trust, Heart Foundation Australia.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
When making the case for the promotion of healthy lifestyle behaviours, statistics that quantify the burden of reciprocal unhealthy behaviours are often cited. For example, physical inactivity is responsible for 6–4% of global premature mortality, insufficient fruit and vegetable consumption for 11·3%, and harmful alcohol consumption for 5–3%; although methodological differences can lead to substantially different results. Some researchers advocate that stressing the harms of unhealthy behaviours can strengthen the case in promoting healthy lifestyles. We suggest that an alternative strategy is to present the complementary positive, gain-framed message that clarifies to what extent existing healthy behaviours have already reduced burdens of disease and mortality.

In this Article, we describe and explore the use of the prevented fraction for the population (PFP), defined as the proportion of a disease outcome or mortality that has been averted or prevented due to the presence of a protective factor (panel).

This is not a new concept: it was first proposed by Miettinen in 1974, and is included in the International Epidemiological Association’s A Dictionary of Epidemiology, and the Encyclopedia of Epidemiologic Methods of the Wiley Reference Series in Biostatistics. PFP is a concept closely related to population attributable fraction (PAF), defined as the proportion of disease cases or mortality cases attributable to a harmful risk factor in other words, the proportion that could be averted or prevented if a harmful risk factor was eliminated. The appendix (pp 1–2) presents graphical depictions of the two concepts. PAF would provide an aspirational indicator of what could be achieved if all members of the public adopted a healthy behaviour. Under most circumstances, such widespread adoption would need new investment and resources. Conversely, PFP can be used as a positive...


**Research in context**

**Evidence before this study**

The case for promoting healthy lifestyle behaviours is often framed negatively in terms of the harm (disease and death) that can be attributed to the absence of healthy behaviours or presence of unhealthy behaviours. In an initial literature search we aimed to identify examples of use of prevented fraction for the population (PFP) relating to lifestyle behaviours, such as physical activity, diet and nutrition, alcohol, and smoking. Because of the variety of terms used for the concept, we searched PubMed and Web of Science for the terms “prevented fraction”, “preventive fraction” and “preventable fraction”. We searched for papers published from database inception until June 12, 2019, without language restrictions. Compared with the thousands of studies on disease or mortality burden, we identified only 12 published studies that used a version of PFP to estimate the proportion of a disease or mortality burden that is already being averted or prevented by existing prevalence of a healthy behaviour. However, no studies had estimated prevented fraction at a global level for total physical activity behaviour, nor had the recommended formula for addressing confounding been used.

**Added value of this study**

To the best of our knowledge, this study is the first to quantify the effect that existing total physical activity prevalence has had on averting premature mortality at the global, regional, and country levels. We showed that during 2001–16 across 168 countries, the median PFP for premature mortality averted by existing physical activity prevalence was 15·0%, conservatively equating to 3·9 million deaths averted annually. We also provided information at a regional level: Africa had the highest median PFP, indicating the greatest percentage of premature mortality averted by physical activity. The Americas had the lowest prevented fraction, closely followed by the Eastern Mediterranean region. We further identified a tendency towards increased prevented fractions in lower income countries compared with higher income countries, and in men compared with women.

**Implications of all the available evidence**

PFP makes the complementary positive case for physical activity promotion, focusing on the benefits currently accomplished rather than the harms from insufficient compliance to recommended levels. This might be a powerful advocacy tool in terms of persuading policy makers and wider societies that physical activity behaviour has quantifiable value, and that existing prevalence should be at least preserved.

Indicator of accomplishment, in terms of how much good is being done or has been done by the amount of existing beneficial behaviours within a population. As such, PFP could be a powerful advocacy tool among policy makers, by promoting positive thinking around healthy lifestyle behaviours (ie, “look how much benefit this behaviour is already providing; let’s create more benefit by increasing prevalence of the behaviour further”). Although this approach has the risk of causing complacency (ie, “the behaviour is already providing benefit, why invest in more?”), it could also be a lever to protect and maintain services. As such, this could be a potentially powerful approach with realistic targets in challenging economic climates.

The few studies that have used PFP are not easy to trace because of inconsistency in terminology. The terms preventive fraction and preventable fraction are variously used. We searched the literature for the three different terms and found the concept in question has been used primarily in oral health, vaccine, and genetic research (appendix pp 3–7). We found 12 examples of use that quantified the proportion of disease burden or mortality burden that had been averted or could have been averted due to a current exposure, in relation to lifestyle behaviours or their physiological markers. Specifically, these studies quantified averted disease or mortality burden due to cycling or walking behaviour or fitness, fruit and vegetable or vitamin consumption, aspirin intake, use of oral contraceptives, sunscreen use, preventive measures for problem drinking, and interventions to prevent fractures. All of these studies determined PFP using formula 2, presented in the panel. Formula 2 is appropriate for scenarios with no confounding factors affecting the relationship between exposure prevalence and the risk of the disease outcome. As the absence of confounding is a rarity in the study of lifestyle behaviours, formula 3 (panel) is preferable, which addresses the potential sources of confounding. To the best of our knowledge, such an approach has not been applied before to global physical activity prevalence.

In this study, we present the first global application of PFP, using formula 3, to obtain estimates of the proportion and number of premature deaths averted by the existing prevalence of physical activity. We obtained results for 168 countries with two counterfactual scenarios for comparison: no activity in the population, and a plausible minimum physical activity prevalence.

**Methods**

**Study design and formulae application**

We did a descriptive study to estimate PFP from the existing prevalence of physical activity for all-cause mortality in 168 countries, using the formula that addresses potential confounding factors (formula 3; panel). The study protocol including all modifications is provided in the appendix (pp 10–11).

---

**Evidence before this study**

The case for promoting healthy lifestyle behaviours is often framed negatively in terms of the harm (disease and death) that can be attributed to the absence of healthy behaviours or presence of unhealthy behaviours. In an initial literature search we aimed to identify examples of use of prevented fraction for the population (PFP) relating to lifestyle behaviours, such as physical activity, diet and nutrition, alcohol, and smoking. Because of the variety of terms used for the concept, we searched PubMed and Web of Science for the terms “prevented fraction”, “preventive fraction” and “preventable fraction”. We searched for papers published from database inception until June 12, 2019, without language restrictions. Compared with the thousands of studies on disease or mortality burden, we identified only 12 published studies that used a version of PFP to estimate the proportion of a disease or mortality burden that is already being averted or prevented by existing prevalence of a healthy behaviour. However, no studies had estimated prevented fraction at a global level for total physical activity behaviour, nor had the recommended formula for addressing confounding been used.

**Added value of this study**

To the best of our knowledge, this study is the first to quantify the effect that existing total physical activity prevalence has had on averting premature mortality at the global, regional, and country levels. We showed that during 2001–16 across 168 countries, the median PFP for premature mortality averted by existing physical activity prevalence was 15·0%, conservatively equating to 3·9 million deaths averted annually. We also provided information at a regional level: Africa had the highest median PFP, indicating the greatest percentage of premature mortality averted by physical activity. The Americas had the lowest prevented fraction, closely followed by the Eastern Mediterranean region. We further identified a tendency towards increased prevented fractions in lower income countries compared with higher income countries, and in men compared with women.

**Implications of all the available evidence**

PFP makes the complementary positive case for physical activity promotion, focusing on the benefits currently accomplished rather than the harms from insufficient compliance to recommended levels. This might be a powerful advocacy tool in terms of persuading policy makers and wider societies that physical activity behaviour has quantifiable value, and that existing prevalence should be at least preserved.

Indicator of accomplishment, in terms of how much good is being done or has been done by the amount of existing beneficial behaviours within a population. As such, PFP could be a powerful advocacy tool among policy makers, by promoting positive thinking around healthy lifestyle behaviours (ie, “look how much benefit this behaviour is already providing; let’s create more benefit by increasing prevalence of the behaviour further”). Although this approach has the risk of causing complacency (ie, “the behaviour is already providing benefit, why invest in more?”), it could also be a lever to protect and maintain services. As such, this could be a potentially powerful approach with realistic targets in challenging economic climates.

The few studies that have used PFP are not easy to trace because of inconsistency in terminology. The terms preventive fraction and preventable fraction are variously used. We searched the literature for the three different terms and found the concept in question has been used primarily in oral health, vaccine, and genetic research (appendix pp 3–7). We found 12 examples of use that quantified the proportion of disease burden or mortality burden that had been averted or could have been averted due to a current exposure, in relation to lifestyle behaviours or their physiological markers. Specifically, these studies quantified averted disease or mortality burden due to cycling or walking behaviour or fitness, fruit and vegetable or vitamin consumption, aspirin intake, use of oral contraceptives, sunscreen use, preventive measures for problem drinking, and interventions to prevent fractures. All of these studies determined PFP using formula 2, presented in the panel. Formula 2 is appropriate for scenarios with no confounding factors affecting the relationship between exposure prevalence and the risk of the disease outcome. As the absence of confounding is a rarity in the study of lifestyle behaviours, formula 3 (panel) is preferable, which addresses the potential sources of confounding. To the best of our knowledge, such an approach has not been applied before to global physical activity prevalence.

In this study, we present the first global application of PFP, using formula 3, to obtain estimates of the proportion and number of premature deaths averted by the existing prevalence of physical activity. We obtained results for 168 countries with two counterfactual scenarios for comparison: no activity in the population, and a plausible minimum physical activity prevalence.

**Methods**

**Study design and formulae application**

We did a descriptive study to estimate PFP from the existing prevalence of physical activity for all-cause mortality in 168 countries, using the formula that addresses potential confounding factors (formula 3; panel). The study protocol including all modifications is provided in the appendix (pp 10–11).
We defined physical activity as meeting the WHO global recommendation of at least 150 min of moderate-intensity aerobic activity, or 75 min of vigorous-intensity activity, or an equivalent combination, throughout one week.\textsuperscript{15} We used population-level, age-standardised and harmonised prevalence data on physical activity for the years 2001–16 for 168 countries, published by Guthold and colleagues,\textsuperscript{16} to estimate the prevalence of physical activity among people who died (P), with the formula:

\[ P = \frac{(P_e \times RR)}{[(P_e \times RR) + (1-P_e)\]} \]

In this formula (denoted formula 4; appendix p 9), P\textsubscript{e} is the prevalence of activity in the population\textsuperscript{16} and RR is the unadjusted relative risk of premature all-cause mortality for active individuals of the population, compared with inactive individuals. The unadjusted RR was taken from a meta-analysis on the association between physical inactivity and all-cause mortality by Lee and colleagues.\textsuperscript{17} We estimated 95% CIs for P\textsubscript{e} using the 95% CIs for P in this formula.

We used the P\textsubscript{e} estimates and adjusted RR, also estimated by Lee and colleagues,\textsuperscript{17} in formula 3 to estimate PFP for each country. To estimate the error conservatively, we generated distributions for P\textsubscript{e} and adjusted RR that reflected their 95% CIs. We used a binomial distribution for P\textsubscript{e} and a normal distribution for the natural log of RR.

Subsequently, we did 10'000 Monte-Carlo simulations, in which each simulation selected one value from the generated P\textsubscript{e} and RR distributions, and used them in formula 2 (panel). We considered the 10'000 estimates produced by the simulations to represent the probability distribution of the true PFP. We present the mean of these simulated values, with the 95% CIs represented by the 2·5th and 97·5th percentiles of the distribution. The appendix presents a graphical overview of the method (p 12), and the parameters for generated prevalence distributions of RR and P\textsubscript{e} (pp 13–21).

Mortality averted estimation
To convert PFP into an estimate of number of premature deaths averted, we obtained the country-specific number of all-cause deaths between the ages of 40–74 years from the mortality datasets of the UN World Population Prospects tool. We chose this age range to reflect the ages at which premature mortality could most plausibly be caused by inactivity. We selected mortality data from July 1, 2010, to June 30, 2015, which is within the period represented by prevalence data, and divided by 5 to estimate annual figures. By dividing the observed number of deaths by 1 minus the prevented fraction, we obtained estimates for the hypothetical total number of deaths that would have been observed had there been no activity in the population in each nation (ie, a zero counterfactual). The total number of premature deaths averted was the difference between the observed and hypothetical totals. A 95% CI range for the estimate of deaths averted was calculated with the lower and upper 95% CIs of the prevented fraction.

In addition to presenting the country-level estimates, we summarised the results by WHO region, and by 2019 World Bank income classification;\textsuperscript{18} each of these groupings were further subdivided into gender-specific results according to the UN mortality datasets. Countries without an income categorisation (Cook Islands, Niue, occupied Palestinian territory, and Tokelau) were classified according to similar neighbouring economies. As these groups of countries were small (often <20) and the estimates did not typically follow a normal distribution, we present group-level medians and ranges to summarise the data; summary values representative of all 168 countries are presented in the same way for comparability.

For 14 nations we were unable to obtain mortality data; these made up less than 0·01% of the world’s population (appendix p 22). For these countries, we imputed mortality data at ages 40–74 years on the basis of the median ratio of deaths to the total population in countries in the same WHO region and World Bank income classified according to similar neighbouring economies. We chose this age range to reflect the ages at which premature mortality could most plausibly be caused by inactivity. We selected mortality data from July 1, 2010, to June 30, 2015, which is within the period represented by prevalence data, and divided by 5 to estimate annual figures. By dividing the observed number of deaths by 1 minus the prevented fraction, we obtained estimates for the hypothetical total number of deaths that would have been observed had there been no activity in the population in each nation (ie, a zero counterfactual). The total number of premature deaths averted was the difference between the observed and hypothetical totals. A 95% CI range for the estimate of deaths averted was calculated with the lower and upper 95% CIs of the prevented fraction.

In addition to presenting the country-level estimates, we summarised the results by WHO region, and by 2019 World Bank income classification; each of these groupings were further subdivided into gender-specific results according to the UN mortality datasets. Countries without an income categorisation (Cook Islands, Niue, occupied Palestinian territory, and Tokelau) were classified according to similar neighbouring economies. As these groups of countries were small (often <20) and the estimates did not typically follow a normal distribution, we present group-level medians and ranges to summarise the data; summary values representative of all 168 countries are presented in the same way for comparability.

For 14 nations we were unable to obtain mortality data; these made up less than 0·01% of the world’s population (appendix p 22). For these countries, we imputed mortality data at ages 40–74 years on the basis of the median ratio of deaths to the total population in countries in the same WHO region and World Bank income
categories; these median ratios were multiplied by the population of the country without mortality data.

Sensitivity analysis
We did three sensitivity analyses. The first two used formula 2: with the unadjusted RR to provide unadjusted results, and with the adjusted RR as this was the method most commonly used in the literature to date (appendix pp 4–7). In the third analysis we used a plausible minimum physical activity prevalence counterfactual. This comparison attempted to focus on the burden averted due to modifiable physical activity prevalence, not including the residual levels (ie, individuals who would be active regardless of initiatives to promote activity). For this comparison, we used the median of the lowest observed prevalence of activity from each region. We opted for this measure rather than the observed lowest prevalence from a single nation because environmental and cultural factors vary widely between regions and might influence activity levels. Using formula 4, we obtained a \( P_d \) for this minimum prevalence of activity. We adapted formula 3 to allow for a non-zero counterfactual, analogous to the population impact fraction formulae often used for PAF (denoted formula 5; appendix pp 23–25). Countries with a prevalence of activity lower than the chosen counterfactual value were excluded from this analysis. All analyses were done in STATA (version 15.1), and forest plots of the data were produced in RStudio (version 1.2.5033).

Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results
For the 168 nations included in this study, the global median PFP (determined with formula 3) was 15·0% (range 6·6–20·5), equating to 3·9 million (95% CI 2·5–5·6) premature deaths averted per year (figure, table).

The WHO region with the highest PFP was Africa (16·6% [12·1–20·5]; equating to 0·5 million deaths (95% CI 0·3–0·7) averted annually) and the region with the lowest prevented fraction was the Americas (13·1% [10·8–16·6]; 0·3 million deaths (95% CI 0·2–0·5) averted annually) closely followed by the Eastern Mediterranean region (13·2% [6·6–18·9]; 0·2 million deaths (95% CI 0·1–0·3); figure, table). The countries with the highest prevented fractions were Mozambique and Uganda (both

| WHO region               | Median PFP, % (range) | Deaths averted, thousands |
|--------------------------|-----------------------|---------------------------|
| Both genders             | 15·0% (6·6–20·5)      | 3·9 (2·5–5·6)             |
| Women                    | 14·1% (5·0–19·4)      | 2·5 (1·4–3·6)             |
| Men                      | 16·0% (7·8–18·8)      | 4·4 (2·7–6·2)             |

(Figure continues on next page)
20.5% [95% CI 14.4–26.2] and the country with the lowest prevented fraction was Kuwait (6.5% [4.0–9.6]; appendix pp 26–36). Similar results were observed for country-level data classified by gender, with women in Niue and men in Tokelau also ranking among the populations with the highest prevented fractions (appendix pp 37–51). The median prevented fraction in countries classified as low income was higher than that in

| Joint region and income classification | Median PFP, % (range) | Deaths averted, thousands |
|--------------------------------------|------------------------|--------------------------|
| Africa: High                         | 17.3% (11.7–17.6)      | 184.7                    |
| Upper-middle                         | 14.5% (12.9–17.3)      | 75.5                     |
| Lower-middle                         | 13.1% (12.4–15.8)      | 6.0                      |
| Low                                  | 14.1% (12.3–13.5)      | 1.2                      |
| Americas: High                       | 14.5% (11.3–17.4)      | 235.4                    |
| Upper-middle                         | 12.1% (10.0–14.7)      | 77.5                     |
| Lower-middle                         | 12.2% (11.7–16.9)      | 3.6                      |
| Low                                  | 12.9% (11.7–13.1)      | 0.9                      |
| Eastern Mediterranean: High          | 14.2% (11.4–17.8)      | 235.4                    |
| Upper-middle                         | 13.6% (10.6–17.7)      | 79.5                     |
| Lower-middle                         | 16.6% (13.9–18.5)      | 189.6                    |
| Low                                  | 17.3% (15.2–19.1)      | 60.1                     |
| South-East Asia: Upper-middle        | 15.2% (14.6–15.9)      | 42.7                     |
| Lower-middle                         | 14.4% (13.5–15.2)      | 17.2                     |
| Low                                  | 16.5% (15.1–16.9)      | 30.5                     |
| Western Pacific: High                | 13.4% (11.8–17.5)      | 81.7                     |
| Upper-middle                         | 12.8% (9.4–16.4)       | 25.1                     |
| Lower-middle                         | 14.9% (12.8–18.5)      | 57.1                     |

*Figure: Median PFP estimates and corresponding number of deaths averted*

No range is presented for region and income groups with only one country. Countries in each region and income group are shown in the appendix (pp 29–36). Deaths averted is for the age range 40–74 years. Number of deaths averted for men and women might not add up to the estimate for both genders because the distributions of deaths across men and women are not even, and differences are magnified when multiplied by a derivative of activity prevalence, which also varies considerably by gender. PFP = prevented fraction for the population.
| WHO region                | Women     | Men       | Both genders | Women     | Men       | Both genders | Women     | Men       | Both genders | Women     | Men       | Both genders |
|--------------------------|-----------|-----------|--------------|-----------|-----------|--------------|-----------|-----------|--------------|-----------|-----------|--------------|
| Africa                   | 16·6%     | 15·8%     | 17·5%        | 25·6%     | 24·0%     | 26·4%        | 17·1%     | 16·4%     | 18·0%        | 6·1%      | 6·9%      | 12·6%         |
| Americas                 | 13·1%     | 12·8%     | 15·0%        | 20·1%     | 19·7%     | 22·9%        | 13·8%     | 13·5%     | 15·6%        | 3·3%      | 4·0%      | 3·9%          |
| Eastern Mediterranean    | 13·2%     | 12·0%     | 14·1%        | 20·8%     | 18·7%     | 21·6%        | 13·9%     | 12·8%     | 14·7%        | 3·1%      | 3·3%      | 3·2%          |
| Europe                   | 14·6%     | 13·8%     | 15·5%        | 22·3%     | 21·1%     | 23·6%        | 15·2%     | 14·4%     | 16·1%        | 3·9%      | 4·7%      | 3·6%          |
| South-East Asia          | 16·1%     | 15·0%     | 17·2%        | 24·8%     | 22·9%     | 25·9%        | 16·7%     | 15·6%     | 17·7%        | 5·6%      | 6·1%      | 5·6%          |
| Western Pacific          | 15·5%     | 14·2%     | 17·2%        | 23·6%     | 21·8%     | 25·9%        | 16·1%     | 14·9%     | 17·7%        | 5·2%      | 5·9%      | 5·9%          |
| World Bank income group classification |          |           |              |           |           |              |           |           |              |           |           |               |
| High                     | 14·1%     | 13·0%     | 15·0%        | 21·6%     | 20·1%     | 22·9%        | 14·7%     | 13·8%     | 15·7%        | 3·4%      | 3·1%      | 3·1%          |
| Upper-middle             | 14·0%     | 13·1%     | 15·1%        | 21·5%     | 20·3%     | 23·1%        | 14·7%     | 13·8%     | 15·8%        | 3·8%      | 3·5%      | 3·5%          |
| Lower-middle             | 16·5%     | 15·8%     | 17·3%        | 24·9%     | 24·0%     | 26·6%        | 17·0%     | 16·4%     | 17·8%        | 6·0%      | 7·0%      | 6·0%          |
| Low                      | 17·9%     | 17·2%     | 18·7%        | 26·9%     | 25·9%     | 27·8%        | 18·3%     | 17·7%     | 19·0%        | 7·7%      | 8·5%      | 7·3%          |

Deaths averted between ages 40–74 years, thousands (Main analysis)

| WHO region                | Women     | Men       | Both genders | Women     | Men       | Both genders | Women     | Men       | Both genders | Women     | Men       | Both genders |
|--------------------------|-----------|-----------|--------------|-----------|-----------|--------------|-----------|-----------|--------------|-----------|-----------|--------------|
| Africa                   | 15·0%     | 15·7%     | 15·3%        | 22·8%     | 21·6%     | 23·5%        | 15·6%     | 16·7%     | 16·6%        | 4·0%      | 5·1%      | 4·3%          |
| Americas                 | 15·2%     | 15·0%     | 15·1%        | 22·8%     | 21·6%     | 23·5%        | 15·6%     | 16·7%     | 16·6%        | 4·0%      | 5·1%      | 4·3%          |
| Eastern Mediterranean    | 15·2%     | 14·8%     | 15·0%        | 22·8%     | 21·6%     | 23·5%        | 15·6%     | 16·7%     | 16·6%        | 4·0%      | 5·1%      | 4·3%          |
| Europe                   | 15·2%     | 14·8%     | 15·0%        | 22·8%     | 21·6%     | 23·5%        | 15·6%     | 16·7%     | 16·6%        | 4·0%      | 5·1%      | 4·3%          |
| South-East Asia          | 15·2%     | 14·8%     | 15·0%        | 22·8%     | 21·6%     | 23·5%        | 15·6%     | 16·7%     | 16·6%        | 4·0%      | 5·1%      | 4·3%          |
| Western Pacific          | 15·2%     | 14·8%     | 15·0%        | 22·8%     | 21·6%     | 23·5%        | 15·6%     | 16·7%     | 16·6%        | 4·0%      | 5·1%      | 4·3%          |

(Table continues on next page)
### WHO region and World Bank income group classification

| Region          | High          | Upper-middle  | Lower-middle | Low           |
|-----------------|---------------|---------------|--------------|---------------|
| Africa          | 17.3% (12.8–16.6) | 14.3% (10.8–15.5) | 15.9% (12.1–20.3) | 17.9% (12.3–20.5) |
| Americas        | 14.5% (11.7–16.4) | 13.0% (9.9–17.3) | 13.2% (9.3–18.6) | 17.2% (13.8–20.6) |
| Eastern Mediterranean | 12.1% (6.6–14.0) | 13.0% (7.8–14.7) | 14.4% (9.3–18.4) | 18.7% (13.8–20.6) |
| Europe          | 14.2% (11.4–17.8) | 13.6% (10.1–17.8) | 15.0% (12.3–17.6) | 25.9% (16.9–30.1) |

### Deaths averted between ages 40–74 years, thousands (Main analysis)

| Gender          | Deaths averted | Deaths averted | Deaths averted | Deaths averted |
|-----------------|----------------|----------------|----------------|----------------|
| Women           | 17.9% (12.1–20.3) | 12.6% (9.3–18.4) | 15.9% (14.1–16.8) | 18.7% (13.8–20.6) |
| Men             | 17.0% (12.4–17.3) | 13.0% (9.9–17.3) | 15.9% (14.1–16.8) | 25.9% (16.9–30.1) |

**Main adjusted estimate (0% activity counterfactual)**

**Unadjusted estimate (0% activity counterfactual)**

**Partially adjusted estimate (0% activity counterfactual)**

**Adjusted estimate (54.3% active counterfactual)**

(Continued from previous page)

### Partially adjusted estimate (0% activity counterfactual)

| Region          | Both genders | Women | Men | Both genders | Women | Men | Both genders | Women | Men | Both genders | Women | Men |
|-----------------|--------------|-------|-----|--------------|-------|-----|--------------|-------|-----|--------------|-------|-----|
| Africa          | 17.3% (12.8–16.6) | 17.0% (10.8–15.5) | 17.5% (14.9–17.6) | 26.0% (19.8–25.0) | 25.6% (16.8–23.6) | 26.4% (22.7–26.5) | 17.7% (13.5–17.0) | 17.5% (11.5–16.1) | 17.9% (15.5–18.2) | 6.9% (3.6–6.2) | 8.3% (4.7–8.6) | 5.9% (3.4–5.6) |
| Americas        | 14.5% (11.7–16.4) | 12.5% (9.0–15.6) | 15.8% (12.9–17.3) | 22.2% (18.2–24.8) | 19.4% (14.2–23.7) | 24.0% (20.0–26.0) | 15.1% (12.4–17.0) | 13.2% (9.7–16.2) | 16.4% (13.6–17.7) | 3.8% (0.6–6.0) | 3.9% (1.1–6.8) | 4.0% (0.7–6.7) |
| Eastern Mediterranean | 12.1% (6.6–14.0) | 10.3% (7.8–14.7) | 12.6% (8.1–19.1) | 18.7% (10.5–21.5) | 16.2% (12.4–22.4) | 19.5% (15.5–30.0) | 12.8% (7.2–14.6) | 11.0% (6.5–15.3) | 13.3% (8.4–15.3) | 2.2% (1.3–3.2) | 1.4% (0.9–3.1) | 1.8% (0.9–3.7) |
| Europe          | 14.2% (11.4–17.8) | 13.6% (10.1–17.8) | 15.0% (12.3–17.6) | 21.7% (17.8–26.7) | 20.8% (15.8–26.9) | 22.9% (19.1–26.5) | 14.8% (12.1–18.2) | 14.3% (10.8–18.4) | 15.7% (13.1–18.0) | 3.4% (0.3–7.5) | 4.5% (0.6–9.3) | 3.1% (0.0–6.1) |

(Continued from previous page)
### Table: PFP estimates and corresponding number of deaths averted in main and sensitivity analyses

| Region            | PFP, % | Deaths averted between ages 40–74 years, thousands (Main analysis) | Main adjusted estimate (0% activity counterfactual)* | Unadjusted estimate (0% activity counterfactual)† | Partially adjusted estimate (0% activity counterfactual)‡ | Adjusted estimate (54.3% active counterfactual)§ |
|-------------------|--------|-------------------------------------------------------------------|------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-----------------------------------------------|
|                   |        |                                                                  | Both genders | Women | Men | Both genders | Women | Men | Both genders | Women | Men | Both genders | Women | Men |
|                   |        |                                                                  | Both genders | Women | Men | Both genders | Women | Men | Both genders | Women | Men | Both genders | Women | Men |
| **Upper-middle**  |        |                                                                  | 15% (14%–16%) | 3% (2%–5%) | 2% (1%–4%) | 15% (14%–16%) | 3% (2%–5%) | 2% (1%–4%) | 15% (14%–16%) | 3% (2%–5%) | 2% (1%–4%) | 15% (14%–16%) | 3% (2%–5%) | 2% (1%–4%) |
|                   |        |                                                                  | (12–18)      | (10–20) | (10–20) | (12–18)      | (10–20) | (10–20) | (12–18)      | (10–20) | (10–20) | (12–18)      | (10–20) | (10–20) |
| **Lower-middle**  |        |                                                                  | 17% (16%–18%) | 4% (3%–6%) | 4% (3%–6%) | 17% (16%–18%) | 4% (3%–6%) | 4% (3%–6%) | 17% (16%–18%) | 4% (3%–6%) | 4% (3%–6%) | 17% (16%–18%) | 4% (3%–6%) | 4% (3%–6%) |
|                   |        |                                                                  | (15–19)      | (12–21) | (12–21) | (15–19)      | (12–21) | (12–21) | (15–19)      | (12–21) | (12–21) | (15–19)      | (12–21) | (12–21) |
| **Low**           |        |                                                                  | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) |
|                   |        |                                                                  | (13–17)      | (11–19) | (11–19) | (13–17)      | (11–19) | (11–19) | (13–17)      | (11–19) | (11–19) | (13–17)      | (11–19) | (11–19) |
| **South-East Asia** |      |                                                                  | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) |
|                   |        |                                                                  | (13–17)      | (11–19) | (11–19) | (13–17)      | (11–19) | (11–19) | (13–17)      | (11–19) | (11–19) | (13–17)      | (11–19) | (11–19) |
| **Western Pacific** |       |                                                                  | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) | 15% (14%–16%) | 2% (1%–4%) | 2% (1%–4%) |
|                   |        |                                                                  | (13–17)      | (11–19) | (11–19) | (13–17)      | (11–19) | (11–19) | (13–17)      | (11–19) | (11–19) | (13–17)      | (11–19) | (11–19) |

Data are median (range) or number (95% CIs). No range is presented for combined region and income groups with only one country. Countries in each region and income group are shown in the appendix (pp 29–36). Number of deaths averted for men and women might not add up to the estimate for both genders because the distributions of deaths across men and women are not even, and differences are magnified when multiplied by a derivative of activity prevalence, which also varies considerably by gender. PFP=prevented fraction for the population. RR=relative risk. *The main estimates calculated with formula 3 (panel), the adjusted RR, and 0% activity counterfactual. †The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. §The adjusted estimates calculated with formula 5 (appendix pp 23–25), the adjusted RR, and 54.3% active counterfactual; countries with a negative PFP (activity prevalence <54.3%) were excluded.
lower-middle-income countries (17·9% [range 12·3–20·5] vs 16·5% [12·1–20·3]; figure, table). In turn, lower-middle-income countries showed a higher prevented fraction than countries classified as upper-middle income (14·0% [9·5–18·9]) or high income (14·1% [6·6–17·8]). We identified a broad pattern of higher median prevented fractions for countries of lower income classifications within most regions, but the ranges overlapped.

The global median PFP was 14·1% (5·0–20·4) for women and 16·0% (7·8–20·7) for men (figure, table, appendix pp 37–51). The regional median prevented fraction values were between 1·7 and 3·0 percentage points lower for women, with the greatest difference in the Western Pacific region. The median prevented fraction values based on World Bank income classification were between 1·5 and 2·0 percentage points lower for women, with slightly greater differences between men and women in higher income countries than in lower income countries. We estimated that 1·5 million (95% CI 0·9–2·2) annual deaths had been averted for women and 2·5 million (1·6–3·5) annual deaths for men by existing physical activity prevalence across all countries.

Sensitivity analyses with formula 2 produced higher estimates of the prevented fractions than our main analysis with formula 3. The global median prevented fraction with an unadjusted RR was 22·9% (range 10·5–30·2) and with an adjusted RR was 15·6% (7·2–20·6; table). In our third sensitivity analysis, we used a counterfactual of the median lowest observed prevalence of activity for each region, as opposed to 0% of the population meeting the physical activity guidelines (formula 5). The median lowest prevalence was 54·3%, which corresponded to a PFP of 44·7%. Countries that had a prevalence of activity lower than this counterfactual value were excluded (six countries overall; on gender-specific analyses, nine for women and four for men). In this analysis, global median prevented fraction was 4·5% (0·3–10·5%), which was 11·5 percentage points lower than our previous estimate (table). In all sensitivity analyses, the same patterns according to region, income classification, and gender were evident.

Discussion

Across 168 countries, the median percentage of premature mortality averted was 15·0%, conservatively equating to 3·9 million deaths per year. We identified variations by WHO region and World Bank income classification: Africa had the highest median PFP, while the Americas and Eastern Mediterranean regions had the lowest. Countries with low-income classification tended to have higher prevented fractions than high-income countries. The prevented fractions were higher for men than for women, with similar patterns across regions and income classifications. To the best of our knowledge, these are the first national and global estimates of PFP associated with total physical activity. Furthermore, they are the first estimates derived from a formula that minimises bias from potential confounding in the disease–exposure relationship, and from the unequal distribution of activity across potential confounders. Use of PFP in this way has the potential to create a positive discourse around the existing efforts to promote physical activity.

Global differences in the prevented fractions reflect the differential prevalence of physical activity; estimations of averted deaths also factor in population size and mortality rates among people aged 40–75 years. The policy implications of the differences in activity prevalence have been discussed elsewhere. We view the implications of the present study to be similar across all nations and regions: a positive case can be made about existing amounts of physical activity, and we believe the results and the approach in general are powerful advocacy tools for policy makers and other stakeholders in public health.

Use of PFP could support a positive position on physical activity that might be more conducive to political support than criticism of current policy, by showing the value of existing investment and services, particularly during economic hardship. We encourage the incorporation of these positive messages into the discourse and advocacy around physical activity policy at the global, regional, and country levels; for example, via scenario modelling to support the WHO Global Action Plan on Physical Activity and the contribution of physical activity to the attainment of the Sustainable Development Goals.

PFP is a complementary statistic to PAF, with each supporting a different approach to framing public health advocacy and messaging. PFP compares the current situation with the worst-case scenario, whereas PAF compares against the best-case scenario. Therefore, if activity prevalence increases, we would expect PFP to increase (representing increased benefits being accrued), and PAF to decrease (representing decreased potential for further gains). However, they are not directly comparable as proportions because they have different denominators: the number of deaths in a hypothetical worst-case scenario (PFP), and the number of deaths in the current situation (PAF). With that in mind, we compare our PFP estimate of 15·0% for physical activity with a PAF for physical inactivity, derived with similar methods by Ding and colleagues, of 6·4%. These statistics indicate that, although mortality burden could be reduced by 6·4% by increases in activity, if the prevalence of activity were to decrease to zero, mortality would be 15·0% higher.

Despite PAF being a standard epidemiological approach, one caveat, which also applies to PFP, is that the counterfactual is the most extreme scenario. Some researchers might argue that 0% or 100% of a population meeting the global physical activity recommendations is implausible; others might debate whether a minimum physical activity prevalence exists. We therefore also estimated PFP using a minimum plausible activity prevalence of 54·3% as a counterfactual. The global median prevented fraction was 11·5 percentage points lower than this counterfactual.
lower than when a 0% activity prevalence counterfactual was used (4·5% vs 15·0%). Levine argued that PAF estimates are only meaningful if an intervention can be identified that could cause the assumed reduction in disease or mortality. The equivalent for PFP would be identifying the residual amount of activity that exists regardless of intervention. However, the burden that governments or individual initiatives claim to prevent becomes the quantity that they are responsible for maintaining, and so we believe these statistics have merit as an advocacy tool to start that discussion. Regarding the interpretation of these statistics, two further points should be considered. Firstly, changes in activity prevalence are unlikely to occur independent of other risk factors such as obesity, which causes difficulty in attributing any burden of mortality entirely to one risk factor. Secondly, reductions in premature mortality, despite being a good health indicator, do not necessarily translate to an extended healthy lifespan or a reduced overall burden on the health system.

Assumptions to note in the present study include our treatment of physical activity as a binary exposure, implying no benefits of undertaking a level of activity that is insufficient to meet the global recommendation. We know this not to be the case: the greatest reduction in mortality risk is evident with initial increases in activity at the low end of the activity level spectrum, and further benefits are associated with doing more than the minimum recommended amount. Therefore, we expect our estimates to be conservative. Our method is in line with previous work on the global burden of physical activity that used PAF estimates, but differs from the approach of Global Burden of Disease (GBD) studies, which used a multilevel categorisation of physical activity and the equivalent of our formula. These factors, along with the choices of prevalence and mortality data, and of RR values, make a considerable difference to estimates of PAF. For example, estimates from two different approaches gave a difference of 2 million deaths attributable to physical activity. A 2020 study suggests that the magnitude of RR values for mortality associated with inactivity are increased when derived from accelerometer-measured behaviours. When global activity prevalence estimates are derived from standardised accelerometry protocols, the overall effect on estimates of PFP will be interesting to reassess.

We chose to be conservative by limiting data to deaths occurring between age 40–74 years. This age range matches that of many studies used to derive RR, and avoids counting causes of death that are not directly attributable to physical activity, such as neonatal complications or deaths among the oldest age groups that stretch the definition of avertable. We considered estimating the number of averted deaths in populations with non-communicable disease, but the available data were not provided for each country by age group. This avenue should be considered by future work if the data become available, although the events around coronavirus disease 2019 have brought into focus the role that physical activity might have in promoting immune function and preventing deaths from communicable disease. The number of assumptions required, and the variability in estimates derived from different data sources led Lee and colleagues to question whether such differences make estimates of disease or mortality burden worthless. They concluded that their provision of a reference point still had substantial utility. We concur that these statistics are helpful indications of prevented, preventable, and attributable disease and mortality burdens; a way of translating the results of epidemiological or intervention studies into public health policy and practice. Some situations such as cross-country comparisons will favour use of the prevented fraction, while others such as within-country advocacy might suit the use of the absolute number of deaths averted.

In conclusion, we estimated the median global burden of premature mortality averted by physical activity to be 15·0%, conservatively equating to 3·9 million deaths annually. We propose use of PFP as a complimentary statistic to PAF in promoting healthy lifestyle behaviours, to make the cases of both what has been and of what could be achieved.

Contributors
TS and PK initially designed the study. All authors refined the study design and developed the concept. TS acquired and analysed the data, and drafted the manuscript with PK. All authors interpreted data and critically revised the manuscript. All authors have approved the final version for publication.

Declaration of interests
We declare no competing interests.

Data sharing
All data used in this study are publicly available and are referenced in the manuscript. The STATA code used to run the analyses is available on request.

Acknowledgments
TS, SB, and SJS are funded by the UK Medical Research Council (MRC; MC_UU_12015/1 and MC_UU_12015/3). DD is funded by a Future Leader Fellowship of the Australian Heart Foundation (number 101234). At the time of this work, MT was a member of the UK Centre for Diet and Activity Research, a UK Clinical Research Collaboration (UKCRC) Public Health Research Centre of Excellence funded by an MRC grant (MR/K023187/1). We gratefully acknowledge funding from the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council, the MRC, the National Institute for Health Research, and the Wellcome Trust, under the auspices of the UKCRC. MT was also funded during his participation in the project “Methods and Tools for Assessing the Health Impacts of Transport: modelling study” (MRC grant MR/P02663X/1).

Editorial note: the *Lancet* Group takes a neutral position with respect to territorial claims in published text and tables and institutional affiliations.

References
1. WHO. Global action plan on physical activity 2018–2030: more active people for a healthier world. Geneva: World Health Organization, 2018.
Articles

2 WHO. Food and Agriculture Organization of the United Nations. Driving commitment for nutrition within the UN decade of action on nutrition: policy brief (WHO/NMH/NHD/I711). Geneva: World Health Organization, 2018.

3 WHO. Global status report on alcohol and health 2018. Geneva: World Health Organization, 2018.

4 Ding D, Lawson KD, Kolbe-Alexander TL, et al. The economic burden of physical inactivity: a global analysis of major non-communicable diseases. Lancet 2016; 388: 1311–24.

5 Aune D, Giovannucci E, Boffetta P, et al. Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies. Int J Epidemiol 2017; 46: 1029–56.

6 Lee I-M, Bauman AE, Blair SN, et al. Annual deaths attributable to physical inactivity: whither the missing 2 million? Lancet 2013; 381: 992–93.

7 Lim SS, Carnahan E, Danaei G, et al. Annual deaths attributable to physical inactivity: whither the missing 2 million? — Authors’ reply. Lancet 2013; 381: 993.

8 Wen CP, Wu X. Stressing harms of physical inactivity to promote exercise. Lancet 2012; 380: 192–93.

9 Latimer AE, Brayne LR, Bassett RL. A systematic review of three approaches for constructing physical activity messages: what messages work and what improvements are needed? Int J Behav Nutr Phys Act 2010; 7: 16.

10 International Epidemiological Association. A dictionary of epidemiology, 6th edn. New York, NY: Oxford University Press, 2014.

11 Benichou J. A review of adjusted estimators of attributable risk. Stat Methods Med Res 2001; 10: 195–216.

12 Miettinen OS. Proportion of disease caused or prevented by a given exposure, phenotype, or intervention. Am J Epidemiol 1974; 99: 325–32.

13 Gail MH, Benichou J. Encyclopedia of epidemiologic methods. West Sussex: Wiley, 2000.

14 Greenland S. Concepts and pitfalls in measuring and interpreting attributable fractions, prevented fractions, and causation probabilities. Ann Epidemiol 2015; 25: 155–61.

15 WHO. Global recommendations on physical activity for health. Geneva: World Health Organization, 2010.

16 Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1·9 million participants. Lancet Glob Health 2018; 6: e1077–86.

17 Lee I-M, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012; 380: 219–29.

18 The World Bank. World Bank country and lending groups 2019. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed May 12, 2020).

19 International Society for Physical Activity and Health. The Bangkok declaration on physical activity for global health and sustainable development. Br J Sports Med 2017; 51: 1389–91.

20 Brownson RC, Boehmer TK, Luke DA. Declining rates of physical activity in the United States: what are the contributors? Ann Rev Public Health 2005; 26: 421–43.

21 Levine B. What does the population attributable fraction mean? Prev Chronic Dis 2007; 4: A14.

22 Sallis JF, Owen N, Fisher EB. Ecological models of health behavior. In: Glanz K, Rimer BK, Viswanath K, eds. Health behavior and health education: theory, research and practice, 4th edn. San Francisco, CA: Jossey-Bass, 2008.

23 Manourmnia MA, Altman DG. Population attributable fraction. BMJ 2018; 360: k797.

24 Mytton OT, Tainio M, Ogilvie D, Panter J, Cobiac L, Woodcock J. The modelled impact of increases in physical activity: the effect of both increased survival and reduced incidence of disease. Eur J Epidemiol 2017; 32: 135–50.

25 Physical Activity Guidelines Advisory Committee. 2018 Physical activity guidelines advisory committee scientific report. Washington, DC: US Department of Health and Human Services, 2018.

26 Blond K, Brinkklev CF, Ried-Larsen M, Crippa A, Grøntved A. Association of high amounts of physical activity with mortality risk: a systematic review and meta-analysis. Br J Sports Med 2019; published online Aug 12. DOI:10.1136/bjsports-2018-100393.

27 Sallis JF, Bull F, Guthold R, et al. Progress in physical activity over the Olympic quadrennium. Lancet 2016; 388: 332–36.

28 Ekelund U, Dalene KE, Tarp J, Lee IM. Physical activity and mortality: what is the dose response and how big is the effect? Br J Sports Med 2020; published online Jan 21. DOI:10.1136/bjsports-2019-101765.

29 Hamer M, O’Donovan G, Stamatakis E. Lifestyle risk factors, obesity and infectious disease mortality in the general population: linkage study of 97 844 adults from England and Scotland. Prev Med 2019; 123: 65–70.